NCT05935852

Brief Summary

The objective of the proposed study is to assess gastric emptying time (GET) based on contrast-enhanced multispectral optoacoustic imaging (CE-MSOT) in a collective of patients with type 1 diabetes mellitus (T1DM). The results will be correlated with disease duration and severity.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2023

Shorter than P25 for not_applicable

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 28, 2023

Completed
9 days until next milestone

First Posted

Study publicly available on registry

July 7, 2023

Completed
8 days until next milestone

Study Start

First participant enrolled

July 15, 2023

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2023

Completed
23 days until next milestone

Study Completion

Last participant's last visit for all outcomes

December 24, 2023

Completed
Last Updated

July 7, 2023

Status Verified

June 1, 2023

Enrollment Period

5 months

First QC Date

June 28, 2023

Last Update Submit

June 28, 2023

Conditions

Keywords

diabetic gastroparesisMSOT

Outcome Measures

Primary Outcomes (1)

  • Gastric emptying time

    Gastric emptying time based on MSOT imaging of ICG-signal intensity

    6 hours

Secondary Outcomes (2)

  • Correlation of acquired hemoglobin signal with disease activity

    6 hours

  • Correlation of acquired hemoglobin signal with disease duration

    6 hours

Study Arms (4)

Study group 1

OTHER

Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged\> 18 years, with diabetic neuropathy

Device: Multispectral Optoacoustic Tomography (MSOT)

Study group 2

OTHER

Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged\> 18 years, without diabetic neuropathy

Device: Multispectral Optoacoustic Tomography (MSOT)

Study group 3

OTHER

Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged \< 18 years, disease activity 5 - 10 years, HbA1c \> 8,5%

Device: Multispectral Optoacoustic Tomography (MSOT)

Study group 4

OTHER

Multispectral Optoacoustic Tomography (MSOT) of the gastric antrum and terminal ileum in patients with T1DM, aged \< 18 years, disease activity 5 - 10 years, HbA1c \< 7,5%

Device: Multispectral Optoacoustic Tomography (MSOT)

Interventions

Non-invasive transcutaneous imaging of endogenous and exogenous chromophores via infrared and near-infrared laser pulses

Study group 1Study group 2Study group 3Study group 4

Eligibility Criteria

Age5 Years+
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may not qualify if:

  • Generality:
  • Pregnancy
  • Breastfeeding mothers
  • Tattoo in the area of the examination
  • Subcutaneous fat tissue over 3 cm
  • Known hypersensitivity to ICG, sodium iodide or iodine
  • Hyperthyroidism, focal or diffuse thyroid autonomy
  • Timely close treatment to check thyroid function with ingestion of radioactive iodine (within two weeks before or after the study)
  • Impaired renal function
  • Taking the following medications: Beta blockers, anticonvulsants, cyclopropane, bisulfite compounds, haloperidol, heroin, meperidine, metamizole, methadone, morphine, nitrofurantoin, opium alkaloids, phenobarbital, phenylbutazone, probenecid, rifamycin, any injection containing sodium bisulfite

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
DIAGNOSTIC
Intervention Model
PARALLEL
Model Details: Four Arms with different disease activity and duration
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PD Dr. med. Ferdinand Knieling

Study Record Dates

First Submitted

June 28, 2023

First Posted

July 7, 2023

Study Start

July 15, 2023

Primary Completion

December 1, 2023

Study Completion

December 24, 2023

Last Updated

July 7, 2023

Record last verified: 2023-06